Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK7418
rolofyline · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | rolofyline 2.5 mg IV QD |
| 2 | EXPERIMENTAL | rolofyline 15 mg IV QD |
| 3 | EXPERIMENTAL | rolofyline 30 mg IV QD |
| 4 | EXPERIMENTAL | rolofyline 60 mg IV QD |
| 5 | PLACEBO_COMPARATOR | placebo for rolofyline IV QD |
| Name | Type | Description |
|---|---|---|
| rolofyline | DRUG | rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days |
| Comparator Placebo (unspecified) | DRUG | Matching placebo for rolofyline IV QD; 3 days |
Inclusion Criteria: * Be able to provide written informed consent, * Be a male or female at least 18 years of age, * Be hospitalized for fluid overload requiring IV diuretic therapy * History of use of diuretic therapy for CHF (including this admission), * Be admitted to the hospital within 36 hour...
Rolofyline is an investigational small molecule being studied for congestive heart failure, including in patients with renal impairment. It was evaluated in a Phase 2 trial examining its effects on diuresis and renal function. It is not an approved therapy and remains in clinical development.
Rolofyline is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 2 clinical program for the drug in congestive heart failure.
Rolofyline is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for any indication.
Rolofyline has been studied in one completed Phase 2 trial, NCT00652782, titled Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients. The trial enrolled 160 adults with congestive heart failure and renal impairment and was randomized, double-blind, and placebo-controlled.
Yes, MK7418 is an alternative name for rolofyline. The Phase 2 trial NCT00652782 was conducted under the MK7418 designation, so searches for either name refer to the same Merck investigational compound for congestive heart failure.